Intellia Therapeutics (NTLA) Faces +76% Upside to $20 Analyst Target

Key Takeaways

• The central target of $20 is the arithmetic mean of roughly 16 current, firm-attributed analyst price targets for Intellia Therapeutics, Inc. (NTLA), a clinical-stage CRISPR gene-editing biotechnology company.
• With shares trading near $11.35, reaching $20 would require upside of about 76% — a very large move that hinges mainly on a pivotal regulatory decision.
• Individual targets are unusually wide, spanning roughly $8 to $49, reflecting deep disagreement over pipeline safety versus commercial opportunity.
• The strongest support is lonvo-z, a potential first-in-class one-time treatment for hereditary angioedema (HAE) awaiting an FDA decision by March 2027.
• The biggest risk is the safety overhang in the nex-z ATTR amyloidosis program, combined with ongoing cash burn and no approved products yet.
• You can read more about this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
• Explore Trending AI Robots for automated, AI-driven market analysis across thousands of instruments.

Diving Into the Analyst Consensus

The $20 central target is not a single analyst's call or an official published consensus; it is the arithmetic mean of about 16 firm-level targets I reviewed, rounded to a clean level. The range is exceptionally wide — from $8 at J.P. Morgan and a new $8 Underweight initiation at Barclays, up to $49 at Canaccord Genuity — because analysts weight two competing forces very differently.

Bullish names cluster in the $24 to $30 area. Evercore ISI upgraded the stock to Outperform with a $24 target, while JonesTrading ($27), H.C. Wainwright ($25), and Leerink Partners ($29) argue that approval of the HAE therapy would validate Intellia's entire in vivo CRISPR platform. Cautious firms such as Goldman Sachs ($9, Sell) and J.P. Morgan ($8) focus instead on the ATTR safety questions and the company's pre-revenue status. In between sit Neutral ratings from Bank of America ($16, trimmed from $17), Morgan Stanley and Wells Fargo (both $15), Wedbush ($13), and Bernstein ($17). When I reviewed the data with Tickeron’s AI Screener, it helped put these divergent views in context against peers.

Where NTLA Stands Today and the Road to $20

Intellia Therapeutics (NTLA) trades near $11.35 with a market capitalization of roughly $1.6 billion, well below its 52-week high. Reaching $20 implies a move of about 76%, which qualifies as a very large gain rather than a modest step. The path would most plausibly run through the FDA's decision on lonvo-z for HAE, expected by March 10, 2027. A positive outcome could reshape how investors value the broader CRISPR platform, while a negative or delayed decision would likely keep shares pinned near current levels. Because the company has no marketed products, its value today is almost entirely tied to pipeline probabilities rather than current earnings or revenue. I also checked this using Tickeron’s AI Trend Prediction Engine to see how the stock compares to others in the industry.

Catalysts That Could Push Toward the Target

• Lonvo-z regulatory catalyst: The FDA accepted the biologics license application (BLA) with priority review in September 2026, setting up a decision by March 2027 that could make it the first in vivo CRISPR-based therapy.
• Strong Phase 3 efficacy: Reported data showed roughly an 87% reduction in HAE attack rates and a clean safety profile — a compelling profile for a one-time therapy.
• Financial runway: Cash and marketable securities of about $614.8 million, plus a non-dilutive term loan facility of up to $400 million from OrbiMed, fund operations into 2028.
• Platform optionality: Partnerships with Regeneron and progress on the nex-z ATTR program preserve long-term upside if safety concerns are resolved.

Key Risks on the Horizon

• ATTR safety overhang: Prior liver-safety events and clinical holds in the nex-z ATTR amyloidosis program triggered multiple downgrades and target cuts, and unresolved safety questions remain a key gating risk.
• Pre-revenue losses: Third-quarter 2026 results showed a wider-than-expected loss of $0.91 per share and revenue of just $7.2 million, down 48% year over year.
• Regulatory and commercial uncertainty: Even if lonvo-z is approved, payer acceptance, pricing, and physician adoption for a first-of-its-kind therapy are unproven.
• High short interest and binary risk: The stock carries a large short position, and binary clinical or regulatory outcomes can produce sharp moves in either direction.

Looking at the Charts and Technical Setup

NTLA has traded in a wide range over the past year, with a 52-week low around $8 serving as major support and the prior 52-week high above $18 acting as a longer-term resistance zone. The $10 area is a notable psychological level, while a sustained move above roughly $15 would represent a meaningful recovery toward the mid-range of analyst targets. Reaching $20 would require clearing well-defined resistance near the 52-week high, consistent with the very large move implied by the target.

What to Watch in the Coming Months

Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms may differ. The single most important item is the FDA's decision on lonvo-z, expected by March 2027. Beyond that, investors should track the safety and enrollment progress of the nex-z ATTR studies, quarterly cash-burn figures and any updated runway guidance, analyst rating and target revisions, and the company's commercial-readiness updates ahead of a potential launch.

Using Tickeron’s AI Daily Buy/Sell Signals in Practice

In my own research process, Tickeron’s AI Daily Buy/Sell Signals provide a useful layer for monitoring event-driven names like this one. The tool continuously scans thousands of stocks and ETFs to flag Buy, Sell, or Hold opportunities based on technical shifts and AI analysis, which can help spot trends around binary catalysts without replacing core fundamental work.

Final Assessment

The $20 central target is the rounded arithmetic mean of roughly 16 verified analyst price targets spanning $8 to $49. From a price near $11.35, it represents about 76% upside — a very large move that is defensible only if the FDA approves lonvo-z and the ATTR safety concerns ease. The bulls emphasize the potential first-in-class HAE approval and a clean Phase 3 dataset, while the bears stress the safety overhang, pre-revenue status, and binary regulatory risk. With analyst views this divided, the $20 figure is best understood as a midpoint of sharply divergent scenarios rather than a predictable destination. Investors should monitor the March 2027 FDA decision, nex-z safety updates, cash runway, and subsequent analyst revisions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Scott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking

Notable companies

Industry description

Market Cap

High and low price notable news

Volume